Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor vs Radiotherapy in pCR HNSCC Patients
NCT05980715Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Overall Survival at 5 years and Incidence of Grade 3 and 4 Adverse Reactions at 5 years. Started Jan 2023; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05980715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980715.